Palbociclib is the first-in-class, oral, reversible, highly selective inhibitor of CDK4/6 that has been approved for front-line treatment of metastatic ER+/HER2-breast cancer in combination with an AI (Figure 1). Here, ERBB2 is linked to breast cancer.